Goldman Sachs analyst Matthew Sykes raised the firm’s price target on Bruker to $66 from $58 but keeps a Sell rating on the shares. The company’s Q4 earnings and revenue topped expectations, though the management’s pulling forward of medium term targets is “potentially ambitious”, the analyst tells investors in a research note. The firm adds that it continues to watch operating margins, which have been heavily impacted by acquisitions including PhenomeX, driving the 80bps margin contraction expected for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRKR:
- Bruker Corp Announces Senior Notes Issuance for Corporate Financing
- Bruker Corp Secures CHF 100M in Senior Notes for Growth and Refinancing
- Bruker Corp Announces Private Offering and Financial Strategy
- Bruker announces the acquisition of Japan-based Nanophoton, no terms
- Bruker acquires Spectral Instruments Imaging
